Aureonitol

Details

• Internal ID: 4f63d6ea-5a02-4530-8276-89a4c191b331
• Taxonomy: Organoheterocyclic compounds > Oxolanes
• IUPAC Name: (2S,3R,4S)-2-[(1E)-buta-1,3-dienyl]-4-[(1E,3E)-penta-1,3-dienyl]oxolan-3-ol
• SMILES (Canonical): CC=CC=CC1COC(C1O)C=CC=C
• SMILES (Isomeric): C/C=C/C=C/[C@H]1CO[C@H]([C@@H]1O)/C=C/C=C
• InChI: InChI=1S/C13H18O2/c1-3-5-7-8-11-10-15-12(13(11)14)9-6-4-2/h3-9,11-14H,2,10H2,1H3/b5-3+,8-7+,9-6+/t11-,12-,13+/m0/s1
• InChI Key: DTLKTHCXEMHTIQ-DBCNHVMASA-N
• Popularity: 9 references in papers

Physical and Chemical Properties

• Molecular Formula: C₁₃H₁₈O₂
• Molecular Weight: 206.28 g/mol
• Exact Mass: 206.130679813 g/mol
• Topological Polar Surface Area (TPSA): 29.50 Ų
• XlogP: 2.30
• Atomic LogP (AlogP): 2.24
• H-Bond Acceptor: 2
• H-Bond Donor: 1
• Rotatable Bonds: 4

Synonyms

• 71774-51-1
• (-)-Aureonitol
• 23F04FI61S
• UNII-23F04FI61S
• (2S,3R,4S)-2-[(1E)-buta-1,3-dienyl]-4-[(1E,3E)-penta-1,3-dienyl]oxolan-3-ol
• 3-Furanol, 2-(1,3-butadien-1-yl)tetrahydro-4-(1,3-pentadien-1-yl)-, (2S,3R,4S)-
• CHEMBL4852954
• DTXSID601038840
• AKOS030213172
• NCGC00381388-01
• Q27253745
• (2S,3R,4S)-2-[(1E)-buta-1,3-dien-1-yl]-4-[(1E,3E)-penta-1,3-dien-1-yl]oxolan-3-ol
• (2S,3R,4S)-2-((E)-Buta-1,3-dien-1-yl)-4-((1E,3E)-penta-1,3-dien-1-yl)tetrahydrofuran-3-ol

2D Structure

ADMET Properties (via admetSAR 2)

Target	Value	Probability (raw)	Probability (%)
Human Intestinal Absorption	+	0.9799	97.99%
Caco-2	+	0.7095	70.95%
Blood Brain Barrier	+	0.7500	75.00%
Human oral bioavailability	-	0.6857	68.57%
Subcellular localzation	Mitochondria	0.6227	62.27%
OATP2B1 inhibitior	-	0.8655	86.55%
OATP1B1 inhibitior	+	0.9260	92.60%
OATP1B3 inhibitior	+	0.9682	96.82%
MATE1 inhibitior	-	0.9400	94.00%
OCT2 inhibitior	-	0.8750	87.50%
BSEP inhibitior	-	0.8088	80.88%
P-glycoprotein inhibitior	-	0.9491	94.91%
P-glycoprotein substrate	-	0.8946	89.46%
CYP3A4 substrate	-	0.5109	51.09%
CYP2C9 substrate	-	0.8047	80.47%
CYP2D6 substrate	-	0.8033	80.33%
CYP3A4 inhibition	-	0.9718	97.18%
CYP2C9 inhibition	-	0.9158	91.58%
CYP2C19 inhibition	-	0.8391	83.91%
CYP2D6 inhibition	-	0.9528	95.28%
CYP1A2 inhibition	-	0.7012	70.12%
CYP2C8 inhibition	-	0.8576	85.76%
CYP inhibitory promiscuity	-	0.7568	75.68%
UGT catelyzed	+	0.8000	80.00%
Carcinogenicity (binary)	-	0.8828	88.28%
Carcinogenicity (trinary)	Non-required	0.4898	48.98%
Eye corrosion	-	0.6293	62.93%
Eye irritation	-	0.7736	77.36%
Skin irritation	+	0.5401	54.01%
Skin corrosion	-	0.5944	59.44%
Ames mutagenesis	+	0.6500	65.00%
Human Ether-a-go-go-Related Gene inhibition	-	0.5878	58.78%
Micronuclear	-	0.6400	64.00%
Hepatotoxicity	-	0.6125	61.25%
skin sensitisation	-	0.6854	68.54%
Respiratory toxicity	-	0.6222	62.22%
Reproductive toxicity	-	0.5111	51.11%
Mitochondrial toxicity	-	0.8250	82.50%
Nephrotoxicity	-	0.7301	73.01%
Acute Oral Toxicity (c)	III	0.5596	55.96%
Estrogen receptor binding	-	0.5709	57.09%
Androgen receptor binding	-	0.7746	77.46%
Thyroid receptor binding	-	0.6370	63.70%
Glucocorticoid receptor binding	+	0.6037	60.37%
Aromatase binding	-	0.7712	77.12%
PPAR gamma	+	0.5402	54.02%
Honey bee toxicity	-	0.5521	55.21%
Biodegradation	-	0.5750	57.50%
Crustacea aquatic toxicity	-	0.6000	60.00%
Fish aquatic toxicity	-	0.5836	58.36%

Targets

Proven Targets:

No proven targets yet!

Predicted Targets (via Super-PRED):

CHEMBL ID	UniProt ID	Name	Probability	Model accuracy
CHEMBL226	P30542	Adenosine A1 receptor	90.83%	95.93%
CHEMBL5619	P27695	DNA-(apurinic or apyrimidinic site) lyase	85.76%	91.11%
CHEMBL253	P34972	Cannabinoid CB2 receptor	83.99%	97.25%
CHEMBL241	Q14432	Phosphodiesterase 3A	83.22%	92.94%
CHEMBL3251	P19838	Nuclear factor NF-kappa-B p105 subunit	81.32%	96.09%
CHEMBL1994	P08235	Mineralocorticoid receptor	80.37%	100.00%
CHEMBL1806	P11388	DNA topoisomerase II alpha	80.08%	89.00%

Plants that contains it

There are no matching plants.

Cross-Links

• PubChem: 25064137
• LOTUS: LTS0089527
• wikiData: Q27253745